Skip to content
HomeLatest newsHealth & wellnessBy the numbers: Understanding the toll of inflammatory bowel disease
Person with hand on stomach

By the numbers: Understanding the toll of inflammatory bowel disease

For Colitis and Crohn’s Disease Awareness Week, learn about the challenges of this painful condition—and why Johnson & Johnson continues to seek new treatment options.

Living with Crohn’s disease or ulcerative colitis—collectively known as inflammatory bowel disease (IBD)—isn’t easy. Characterized by chronic inflammation of the digestive tract, IBD is an immune-mediated condition that typically causes diarrhea, weight loss, fatigue and abdominal pain.

But the burden of living with IBD goes beyond the physical pain. People with IBD often talk about the shame and embarrassment of having a “bathroom” disease. No surprise, this can lead to mental health problems such as depression and anxiety.

Treatment for people with IBD has improved dramatically in the past 25 years since biologic drugs entered the picture. But a significant portion of patients don’t respond to these medications or find that they eventually stop working. That’s why Johnson & Johnson is committed to developing new remedies, in addition to precision medicine approaches that will help speed up diagnosis and help healthcare providers match patients to the best treatment.

For Colitis and Crohn’s Disease Awareness Week, we’re taking a look at the impact of this painful condition across the globe—and some of the reasons why hope is on the horizon.

Understanding the toll of inflammatory bowel disease infographic

Have an idea to transform care for BIPOC communities living with IBD?

The Johnson & Johnson Innovation Inflammatory Bowel Disease QuickFire Challenge: Innovating for Health Equity is accepting applications.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.